Evidence map›Paper›PMID 38318160›Full record

ReviewMedComm2024

Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy.

Xiaoting Luo, Xin He, Xingmei Zhang, Xiaohui Zhao, Yuzhe Zhang, Yusheng Shi, Shengni Hua

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoting LuoDepartment of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.
Xin HeDepartment of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.
Xingmei ZhangDepartment of Neurobiology School of Basic Medical Sciences Southern Medical University Guangzhou China.
Xiaohui ZhaoDepartment of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.
Yuzhe ZhangDepartment of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.
Yusheng ShiDepartment of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.
Shengni HuaDepartment of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.ORCID https://orcid.org/0000-0002-6014-1476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a high mortality rate. It is regarded as a significant public health issue because of its complicated pathophysiology, high metastasis, and recurrence rates. There are no obvious symptoms in the early stage of HCC, which often leads to delays in diagnosis. Traditional treatment methods such as surgical resection, radiotherapy, chemotherapy, and interventional therapies have limited therapeutic effects for HCC patients with recurrence or metastasis. With the development of molecular biology and immunology, molecular signaling pathways and immune checkpoint were identified as the main mechanism of HCC progression. Targeting these molecules has become a new direction for the treatment of HCC. At present, the combination of targeted drugs and immune checkpoint inhibitors is the first choice for advanced HCC patients. In this review, we mainly focus on the cutting-edge research of signaling pathways and corresponding targeted therapy and immunotherapy in HCC. It is of great significance to comprehensively understand the pathogenesis of HCC, search for potential therapeutic targets, and optimize the treatment strategies of HCC.

Indexed as

hepatocellular carcinomaimmunotherapysignaling pathwaystargeted therapy

Identifiers

PMID38318160
PMCPMC10838672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.